臨床検査54巻10号

2010年10月発行

記事購入ページに移動

今月の主題 ファーマコゲノミクス 各論

循環器領域における個別化医療と薬剤感受性

著者： 南畝晋平¹ 東純一²

所属機関： ¹兵庫医療大学薬学部薬物動態学 ²兵庫医療大学薬学部臨床ゲノム薬理学

ページ範囲：P.1143 - P.1149

　近年，循環器疾患の個別化医療を目指した研究は，目覚ましい発展を遂げている．先天性QT延長症候群は，そのタイプにより治療方針が異なるが，タイプ分けのための遺伝子診断が2008年4月から本邦で保険適用されている．また，ブシンドロールは，心不全への有効性は否定されていたが，遺伝子多型で被験者を層別化することにより有効性が確認でき，遺伝子多型判定をセットにした承認が，米食品医薬品局(FDA)に申請されている．今後，さらなる研究の発展が期待される．

参考文献

1) Klein TE, Altman RB, Eriksson N, et al:Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med　360：753-764，2009

2) Mega JL, Close SL, Wiviott SD, et al:Cytochrome p450 polymorphisms and response to clopidogrel. N Engl J Med　360：354-362，2009

3) Link E, Parish S, Armitage J, et al:SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med　359：789-799，2008

4) Hedley PL, Jorgensen P, Schlamowitz S, et al:The genetic basis of long QT and short QT syndromes:a mutation update. Hum Mutat　30：1486-1511，2009

5) Lu JT, Kass RS. Recent progress in congenital long QT syndrome. Curr Opin Cardiol，2010

6) Moss AJ, Zareba W, Kaufman ES, et al:Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation　105：794-799，2002

7) Moss AJ, Shimizu W, Wilde AA, et al:Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation　115：2481-2489，2007

8) Rathz DA, Brown KM, Kramer LA, et al:Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol　39：155-160，2002

9) Levin MC, Marullo S, Muntaner O, et al:The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem　277：30429-30435，2002

10) Mason DA, Moore JD, Green SA, et al:A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem　274：12670-12674，1999

11) Mialet Perez J, Rathz DA, Petrashevskaya NN, et al:Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med　9：1300-1305，2003

12) Borjesson M, Magnusson Y, Hjalmarson A, et al:A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J　21：1853-1858，2000

13) Magnusson Y, Levin MC, Eggertsen R, et al:Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther　78：221-231，2005

14) White HL, de Boer RA, Maqbool A, et al:An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure:a MERIT-HF sub-study. Eur J Heart Fail　5：463-468，2003

15) Terra SG, Hamilton KK, Pauly DF, et al:Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics　15：227-234，2005

16) de Groote P, Helbecque N, Lamblin N, et al:Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics　15：137-142，2005

17) Sehnert AJ, Daniels SE, Elashoff M, et al:Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol　52：644-651，2008

18) Chen L, Meyers D, Javorsky G, et al:Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics　17：941-949，2007

19) Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al:A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA　103：11288-11293，2006

20) Kaye DM, Smirk B, Williams C, et al:Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics　13：379-382，2003

21) Lobmeyer MT, Gong Y, Terra SG, et al:Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics　17：277-282，2007

22) Liggett SB, Cresci S, Kelly RJ, et al:A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med　14：510-517，2008

23) Nonen S, Okamoto H, Fujio Y, et al:Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy. Pharmacogenomics J　8：78-84，2008

24) McNamara DM, Holubkov R, Janosko K, et al:Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation　103：1644-1648，2001

25) de Groote P, Helbecque N, Lamblin N, et al:Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail　6：17-21，2004

26) Investigators. B-BEoST. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med　344：1659-1667，2001